Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/21/20 → 7/25/22 |
Funding
- Bristol Myers Squibb Company: $49,404.00
Inflammatory Disease May Predict Outcomes in Patients Treated with Nivolumab or Nivolumab+Ipilumumab
- Adams, Val (PI)
- Black, Penni (CoI)
- Talbert, Jeffery (Former CoI)